Insights


Novel “Tissue-Agnostic” Targeted Treatment

January 14th 2019

Novel Therapeutic Agents for Acute Myeloid and Chronic Lymphocytic Leukemia

January 8th 2019

Advances in the Treatment of Relapsed/Refractory Myeloma

November 22nd 2018

Academic Focus: CAR-T Therapy for Relapsed/Refractory NHL

October 29th 2018

Clinical Update on Differentiated Thyroid Cancer

October 26th 2018

The Hunt for Predictive Markers in Metastatic Colorectal Cancer

October 22nd 2018

Evolution of The Continuum of Care for Metastatic CRC

September 28th 2018

Global Perspectives: FLT3 Inhibitors for AML

September 20th 2018

Novel Predictive Biomarkers for Non-Small Cell Lung Cancer

August 10th 2018

Combination Approaches for Metastatic Renal Cell Carcinoma

July 30th 2018

Global Perspective: CDK4/6 Inhibitors in HR+ Breast Cancer

July 26th 2018

Choosing an Endocrine Partner: Metastatic HR+ Breast Cancer

July 19th 2018

Chemo-Immunotherapy for Non-Driver Metastatic Lung Cancer

July 10th 2018

Practical Perspectives on Treatment of Advanced Gastric/GEJ Cancers

June 26th 2018

TRK Inhibitors: A Tumor Agnostic Targeted Therapy

June 25th 2018

Inside the Clinic: Interdisciplinary Care for Stage IV NSCLC

May 25th 2018

New Treatment Strategies for Hepatocellular Carcinoma

April 24th 2018

Antiangiogenic Therapy in the Current Landscape of NSCLC

April 19th 2018

Treatment Updates in Chronic Lymphocytic Leukemia

March 31st 2018

Treatment Strategies in Neuroendocrine Tumors

March 1st 2018